Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.

Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V.

Langenbecks Arch Surg. 2013 Oct;398(7):989-96. doi: 10.1007/s00423-013-1105-2. Epub 2013 Aug 30.

PMID:
23989613
2.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

3.

Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, Hudemann C, Fendrich V.

Neoplasia. 2014 Jun;16(6):463-70. doi: 10.1016/j.neo.2014.05.010. Epub 2014 Jun 20.

4.

Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Sparn M, Lauth M, Knoop R, Plassmeier L, Bartsch DK, Waldmann J.

Pancreatology. 2013 Sep-Oct;13(5):502-7. doi: 10.1016/j.pan.2013.08.002. Epub 2013 Aug 20.

PMID:
24075515
5.

Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.

Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP.

Cancer Prev Res (Phila). 2013 Oct;6(10):1074-83. doi: 10.1158/1940-6207.CAPR-13-0157. Epub 2013 Aug 20.

6.

RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.

DiNorcia J, Lee MK, Moroziewicz DN, Winner M, Suman P, Bao F, Remotti HE, Zou YS, Yan SF, Qiu W, Su GH, Schmidt AM, Allendorf JD.

J Gastrointest Surg. 2012 Jan;16(1):104-12; discussion 112. doi: 10.1007/s11605-011-1754-9. Epub 2011 Nov 4.

7.

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.

J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.

8.

Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.

Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB.

Oncotarget. 2015 Dec 29;6(42):44509-22. doi: 10.18632/oncotarget.6332.

9.

Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Yip-Schneider MT, Wu H, Hruban RH, Lowy AM, Crooks PA, Schmidt CM.

Pancreas. 2013 Jan;42(1):160-7. doi: 10.1097/MPA.0b013e318254f455.

PMID:
22699205
10.

Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.

Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE.

Neoplasia. 2012 Sep;14(9):778-87.

11.

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.

Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG.

Gastroenterology. 2010 Jul;139(1):292-303. doi: 10.1053/j.gastro.2010.03.034. Epub 2010 Mar 17.

PMID:
20303350
12.

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.

13.

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.

Ocal O, Pashkov V, Kollipara RK, Zolghadri Y, Cruz VH, Hale MA, Heath BR, Artyukhin AB, Christie AL, Tsoulfas P, Lorens JB, Swift GH, Brekken RA, Wilkie TM.

Dis Model Mech. 2015 Oct 1;8(10):1201-11. doi: 10.1242/dmm.020933.

14.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P.

Ann Oncol. 2015 Jun;26(6):1194-200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9.

15.

Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.

Qiu W, Tang SM, Lee S, Turk AT, Sireci AN, Qiu A, Rose C, Xie C, Kitajewski J, Wen HJ, Crawford HC, Sims PA, Hruban RH, Remotti HE, Su GH.

Gastroenterology. 2016 Jan;150(1):218-228.e12. doi: 10.1053/j.gastro.2015.09.013. Epub 2015 Sep 25.

16.

Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.

PLoS One. 2013 Jun 28;8(6):e67330. doi: 10.1371/journal.pone.0067330. Print 2013.

17.

Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.

Yip-Schneider MT, Wu H, Stantz K, Agaram N, Crooks PA, Schmidt CM.

BMC Cancer. 2013 Apr 17;13:194. doi: 10.1186/1471-2407-13-194.

18.

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer.

Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM, Yu W, Maitra A.

Gut. 2008 Oct;57(10):1420-30. doi: 10.1136/gut.2007.148189. Epub 2008 May 30.

19.

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.

Gastroenterology. 2015 Jul;149(1):201-10. doi: 10.1053/j.gastro.2015.04.010. Epub 2015 Apr 14.

20.

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.

Vaz AP, Ponnusamy MP, Rachagani S, Dey P, Ganti AK, Batra SK.

Br J Cancer. 2014 Jul 29;111(3):486-96. doi: 10.1038/bjc.2014.152. Epub 2014 Jul 8.

Supplemental Content

Support Center